Cyclophosphamide–bortezomib–dexamethasone compared with bortezomib–dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma

Eitemau Tebyg

• Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
  gan: Crusoe, Edvan De Queiroz, et al.
  Cyhoeddwyd: (2020)
• Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
  gan: Voorhees, Peter M., et al.
  Cyhoeddwyd: (2020)
• Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
  gan: Ajay K. Nooka, et al.
  Cyhoeddwyd: (2022-04-01)
• Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
  gan: Yimer, Habte, et al.
  Cyhoeddwyd: (2019)
• Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
  gan: Ashrafi, Farzaneh, et al.
  Cyhoeddwyd: (2020)